361 Capital’s Heron Therapeutics HRTX Stock Holding History

361 Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50,171	Closed	-$1.18M	–	333
2019 Q4	$1.18M	Buy	+50,171	New	+$1.11M	0.33%	184

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

361 Capital's HRTX Position: Q1 2020 in Review

361 Capital sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 50,171 shares — an estimated $1.18M sold.

361 Capital first reported a position in HRTX in Q4 2019 and held it in 1 quarter. The position peaked at $1.18M in Q4 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

361 Capital reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
361 Capital sold 50,171 Heron Therapeutics shares in Q1 2020, an estimated $1.18M.
361 Capital first reported a position in Heron Therapeutics in Q4 2019 and held it in 1 quarter.
361 Capital's Heron Therapeutics position peaked at $1.18M in Q4 2019.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.